LOS ANGELES, CA / ACCESSWIRE / April 8, 2019 / Applied Biosciences Corp. (OTCQB: APPB), a diversified cannabinoid therapeutics company focused on the medical, bioceutical, testing and pet health industries, announced that is has retained the Emmes Group to assist with the development and execution of the Company’s partnership and technology licensing initiatives and strategies.
Through this new partnership, Emmes and the Company will work together to formulate a line of medical and scientific focused cannabidiol (“CBD”) based products to target the endocannabinoid system under the “Applied BioPharma” brand.
Applied BioSciences has retained several industry leading individuals as scientific advisory board members and in corporate management consultative capacities. The Company believes that by assembling a well-versed and well-seasoned group of individuals involved in different facets of the medical and scientific business model, the Company will be able to successfully execute and achieve its corporate and therapeutic development goals.
“I am pleased to have the opportunity to work with the Emmes Group, and Martin Schroeder, EVP & Managing Director,” said Chris Bridges, President. “Mr. Schroeder and his colleagues at the Emmes Group have been responsible for helping to build cell therapy assets and developing and executing the business initiatives and licensing strategies for many biotech and pharmaceutical initiatives.” Mr. Bridges further stated.
About Applied BioSciences Corp.
Applied BioSciences Corp. (www.appliedbiocorp.com), is a diversified company focused on multiple areas of the medical, bioceutical and pet health industry. As a leading company in the CBD and Pet health space, the company is currently shipping to the majority of US states as well as to multiple International countries. The company is focused on select investment, consumer brands, and partnership opportunities in the medical, health and wellness, nutraceutical, and pet industries.
About Trace Analytics Inc.
Trace Analytics Inc. is a leading cannabis science and technology company with significant footprints in lab testing, research and development and licensing. Trace Analytics was started by a group of scientists who specialized in analytical chemistry, genetics and molecular biology. The focus of the team is to ensure compliance with public safety standards and
end user safety. Trace Analytics is in the process of expanding throughout the United States, and globally. With the goal of helping the rest of the world adopt “best practices” in cannabis and hemp testing, the company also provides expert consulting services to legislators and regulators in many countries, states and municipalities around the world. For more information, please visit: http://traceanalytics.com.
About Emmes Group
The Emmes Group is a strategy consulting and market research organization supporting firms engaged in the technology and healthcare industries. Our partners have over 50 years of combined experience. We work in partnership with our clients to increase profits and build lasting economic value. Our expertise spans a number of key areas, including: Strategy Consulting, Partnerships, Mergers & Acquisitions, Strategic Marketing, Market Research & Modeling, Business Development, Technology Licensing, Corporate Financing and, Venture Capital Due Diligence. http://www.emmesgroup.com.
To be added to the Applied BioSciences email distribution list, please email firstname.lastname@example.org with APPB in the subject line.
Facebook @remedicbd & @HerbalPetMeds
Instagram @remedishop & @herbal_pet
Twitter @remedishop & @herbal_pet
Safe Harbor Statement
Except for historical information contained herein, statements in this release may be forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “anticipate,” “believe,” “estimate,” “expect,” “intend” and similar expressions, as they relate to Applied Biosciences Corp. (the “Company”) or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the Company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company’s filings with the Securities and Exchange Commission. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as (i) the development and protection of our brands and other intellectual property, (ii) the need to raise capital to meet business requirements, (iii) significant fluctuations in marketing expenses, (iv) the ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of our products and services, (v) the Company’s ability to conduct the business if there are changes in laws, regulations, or government policies related to cannabis, (vi) management’s ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and (vii) other information that may be detailed from time to time in the Company’s filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE: Applied BioSciences Corp.
View source version on accesswire.com: